Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Health Sciences

This article was originally published in The Tan Sheet

Executive Summary

Nutritional supplement maker files for bankruptcy Jan. 29 to facilitate sale of its business "as a going concern" through a competitive bidding process. Chapter 11 filing comes more than a month after GHS filed a breach of contract lawsuit alleging Herbalife reneged on a longstanding oral agreement to use GHS as its sole supplier. Herbalife accounted for roughly 57% of GHS' 1999 sales (1"The Tan Sheet" Jan. 22, p. 13)

You may also be interested in...



NBTY Global Health Sciences $40 Mil. Acquisition Approval Pending

NBTY intends to keep intact bankrupt Global Health Sciences' contract manufacturing business instead of using the acquired capacity for its own purposes, the supplement manufacturer told analysts during a conference call April 26.

NBTY Global Health Sciences $40 Mil. Acquisition Approval Pending

NBTY intends to keep intact bankrupt Global Health Sciences' contract manufacturing business instead of using the acquired capacity for its own purposes, the supplement manufacturer told analysts during a conference call April 26.

NBTY Global Health Sciences $40 Mil. Acquisition Approval Pending

NBTY intends to keep intact bankrupt Global Health Sciences' contract manufacturing business instead of using the acquired capacity for its own purposes, the supplement manufacturer told analysts during a conference call April 26.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel